Brief: EBR Systems Inc - Met Its Primary Safety And Efficacy Endpoints In Its Pivotal Solve-Crt Trial Of Wise Cardiac Resynchronization Therapy System
22/05/2023 14:16
May 22 (Reuters) - EBR Systems Inc EBR.AX :
* EBR SYSTEMS INC - MET ITS PRIMARY SAFETY AND EFFICACY
ENDPOINTS
IN ITS PIVOTAL SOLVE-CRT TRIAL OF WISE CARDIAC RESYNCHRONIZATION
THERAPY SYSTEM
* EBR SYSTEMS INC - WISE SYSTEM IS ON TRACK TO SUBMIT A
PREMARKET
APPROVAL APPLICATION TO FDA IN EARLY 2024
* EBR SYSTEMS INC - FDA HAS GRANTED WISE CRT SYSTEM A
BREAKTHROUGH
DEVICE DESIGNATION, SUPPORTING PRIORITY REVIEW
Source text for Eikon: ID:nPn1f49QSa
Further company coverage: EBR.AX
((reuters.briefs@thomsonreuters.com;))
Recent news on EBR Systems
See all newsAustralia's EBR Systems jumps on filing application for heart treatment
Brief: EBR Systems Submits TGA ARTG Application For Wise® System
Australia's EBR Systems hits record low on weak third-quarter revenue outlook
Brief: EBR Systems Forecasts Q3 2026 Revenue Of US$2.4 MLN To US$2.5 MLN
Brief: EBR Systems Announces Its Plan To Submit A Changes For Supplements To FDA In Q4 2026